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Abstract. The purpose of this research was the preparation of four formulations containing
hydrocortisone acetate (HCA) for topical application, including two aqueous systems (hydrophilic
microemulsion and aqueous gel) and two systems with dominant hydrophobicity (hydrophobic micro-
emulsion and ointment). The formulations were tested for the release and permeation of HCA across an
animal membrane. The release of HCA was found comparable for the four systems. The two
microemulsions promote permeation across an ex-vivo membrane, examined by means of a Franz cell.
Hydrophobic microemulsion guarantees the highest solubility (2,370 μg/ml) and flux (133 μg/cm
2.h) of
the drug, since it contains almost 40% Transcutol, a permeation enhancer. Gel and ointment provide
lower solubility and flux, being the values, related to the ointment, the lowest ones (562 μg/ml and 0.4 μg/
cm
2.h). Experimental results allow the conclusion that gel and ointment can be suitable when it is
desirable to minimize absorption of topically applied HCA as to keep the drug restricted to the diseased
area and prevent side effects of the systemic presence of HCA.
KEY WORDS: gel and ointment; hydrocortisone acetate; microemulsions; transdermal permeability.
INTRODUCTION
Treatment of inflammatory skin diseases frequently
requires a combination of systemic and topical agents, but
topical substances alone are very often adequate (1–5).
As an example, systemic administration of corticoste-
roids is suggested only in the case of acute dermatological
disorders or of chronic diseases, since they are not lacking in
side effects; while topical administration offers the advantage
of avoiding potential problems associated with systemic
exposure of corticosteroids and is, as a consequence, widely
used. In order to minimize absorption, so as to keep the drug
restricted to the diseased area, the action of the drug must be
limited to the surface of the skin and therefore does not need
transdermal permeation: this goal can be achieved by an
appropriate choice both of the pharmaceutical form and/or
excipients present in the formulation (6).
Hydrocortisone acetate (HCA) is a synthetic corticoste-
roid efficient against cutaneous disorders, such as inflamma-
tory dermatitis. Its parent compound hydrocortisone was the
first drug of this class employed in topical formulations for
this purpose: the introduction of the acetate moiety in the 21
position of the steroid ring system improved the topical
activity fivefold. The drug is indicated for the relief of
inflammatory and pruritic manifestations of corticosteroid-
responsive dermatoses. Commercial vehicles for systemic
administration of HCA include rectal suppositories, while
intra-articular injections are used for temporary relief under
certain conditions. Several commercial products containing
HCA are available for topical use on skin (7): formulations
for topical application must allow adequate release of the
active compound, be non-allergenic, non-irritating, and cos-
metically acceptable and, more important, avoid transdermal
permeation of the drug (8). Topical formulations of cortico-
steroids are usually administered in the pharmaceutical form
of ointments, creams, lotions, gels, aerosol sprays, powders
and foams (7). The type of delivery vehicle or formulation of
excipients can markedly affect the penetrating properties and
absorption of the active agent, and thereby affect drug
potency or effectiveness, but also the associated side effects.
In fact, despite belonging to different categories, vehicles are
often structurally similar and affect the diffusion of the active
agent through the matrix and can contain chemical enhancers
promoting transdermal permeation.
Following these suggestions, the purpose of the research
was to test four different formulations for topical administration
of HCA, mainly to evaluate their properties to promote or not
its flux acrossan animal membrane. The formulations examined
in this paper range from an aqueous gel to an ointment, and
from an aqueous to a non-aqueous microemulsion.
MATERIALS
Hydrocortisone acetate was a commercial sample of
pharmaceutical purity (Sigma, Milan, Italy): white powder
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Propylene glycol, 2-(2-ethoxy-ethoxy) ethanol (Trans-
cutol®), caprylo-capryloyl macrogol-8-glyceride (Labrasol®),
oleoyl macrogol-6-glyceride (Labrafil® M 1944CS), propyl-
ene glycol monolaurate (lauroglycol R90®) and polyglyceryl-
6-di-oleate (Plurol oleique®) were gifts from Gattefossé and
were used as received. Liquid paraffin, vaseline oil, Poly-
acrylamide, C13–14 isoparaffin, Laureth-7 (Sepigel 305 Far-
cosgel®) and cellulose acetate dialysis membrane (cutoff
14,000) were purchased from Polichimica (Bologna, Italy).
Equipments
High performance liquid chromatography (HPLC) Wa-
ter Mod. 700 Satellite WISP was employed for analysis,
equipped with: chromatographic column reversed phase 18,
3.9×300 mm Waters; automatic sampling injector Waters
WISP 700; pump Mod. 600 E ultraviolet–visible detector
Mod. 484; data recorder and processor PC-NEC Power Mate.
METHODS
Preparation of the formulations. The quali–quantitative
composition of each vehicle is shown in Table I.
Hydrophilic microemulsion (A)—Prefixed volumes of
three emulsifiers (Transcutol, Labrafil and Labrasol)
were mixed, under magnetic stirring, together with
Plurol oleique that represents the oil phase in this
system. The mixture is added, very slowly, to water.
The microemulsion thus formed, after 1 h rest, was
finally added to the drug powder and stirred for 24 h, in
a dark room.
Aqueous gel (B)—The gel-forming polymer (Sepigel
305) was dispersed in demineralised water under
stirring; after the system has become homogeneous,
the drug is slowly added up to complete dispersion.
Lipophilicmicroemulsion(C)—Transcutol,liquidparaffin
and propylene glycol were added to the emulsifier and
stirred. After 1 h rest, the microemulsion thus formed is
added to the drug under stirring for 24 h, in the absence of
light.
Anhydrous ointment (D)—Vaseline oil and jelly were
mixed, added to the drug and stirred up to homoge-
neous appearance of the formulation.
Solubility determination. HCA equilibrium solubility in
the different vehicles was measured at 25 °C. Excess drug was
added to the different vehicles, which were stirred for 24 h
and then forced through a 0.20 μm nylon filter to remove the
undissolved drug. After filtration an accurately weighed
portion (0.5 g) of each pharmaceutical formulation was
transferred into a 50 ml centrifuge tube and supplemented
with 20 ml acetonitrile solution to extract HCA from each
vehicle: the solvent contained dexamethasone, as internal
standard (10 mg/ml). The mixture was placed in the ultrasonic
bath for 10 min and then centrifuged at 3,000 rpm for 15 min.
10 μl supernatant was assayed for the content in HCA by
HPLC (9).
Release test. The apparatus consists of two compart-
ments. The donor one is a cylinder (9 mm diameter) and
contains the releasing system (2 ml of each formulation); the
drug reaches the receiving phase (40 ml aqueous ethanol 40/
60 v/v) through a semi-permeable cellulose acetate mem-
brane, previously wetted for 10 min. The apparatus is
thermostated at 37 °C. At pre-selected times (1, 2, 3, 4, 5, 6,
7, 8 h) the receptor compartment is renewed with the same
solution and the drug content is analyzed by HPLC.
Permeation experiments. Permeation of HCA from the
four formulations was determined using Franz diffusion cells
fitted with excised pig ear that represents the diffusional
membrane. This consists of the internal portion of the pig ear,
appropriately prepared by elimination of fat tissues. This
study agrees with the protocol approved by the Ethics
Committee at the Faculty of Pharmacy of Bologna Universi-
ty; this research also adheres to the Principles of Laboratory
Animal Care. (NIH publication #85-23, revised in 1985). The
Franz cell (Crown Glass Company Inc. New Jersey, USA)
contains a donor compartment (2.5 ml), where the releasing
system is positioned, separated from the receiving cell
(5.0 ml) by the animal diffusional membrane (64 mm
2).
Membranes are obtained as 2×2 cm samples and after
preparation are kept at −20 °C until used. The membrane is
positioned between the donor and the receptor compartment
of the cell, with the epidermis surface towards the upper
compartment. The formulation (2 ml) to be tested fills the
donor part, while the receiving volume (5 ml) contains
phosphate buffer solution (pH 7.4) to simulate physiological
conditions. Two ml aliquot of the solution of the receptor
compartment is withdrawn at a preset time (1, 2, 3, 4, 5, 6, 7,
8 h) and replaced with the same volume of the buffer at
37 °C. Analysis of the permeated drug was carried out by
means of HPLC, after filtration (0.20 μm) of the sample. All
experiments were carried out in triplicate. The cumulative
amount permeated (μg) divided by the surface area of the
membrane (cm
2) was plotted versus time in hours. J, the
Table I. Weight Percent Composition of the Four Vehicles Examined
(HCA: 0.5% w/w)
%( w/w)
A) Hydrophilic microemulsion
Transcutol 7.97
Labrafil M 1944 CS 4.68
Plurol oleique 6.98
Labrasol 39.02
Water 40.85
B) Aqueous gel
Sepigel 305 3.50
Water 96.50
C) Hydrophobic microemulsion
Transcutol 41.54
Lauroglycol 90 45.08
Propylene glycol 5.50
Vaseline oil 7.88
D) Anhydrous ointment
Vaseline oil 11.51
Vaseline jelly 88.49
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2.h), was obtained as the slope of the
linear portion of the plot. The permeability coefficient, K
(cm/h) was obtained dividing the flux by the concentration
(μg/cm
3) of the dissolved drug in each formulation in the
donor compartment. Permeation parameters are shown in
Tables II and III.
HPLC method. The mobile phase was a mixture of
methanol, acetonitrile and water (15:27:58, v/v/v), degassed
before application. Experimental conditions were as follows:
injection volume 10 μl, the mobile phase isocratically pumped
at a flow rate 0.8 ml/min at room temperature, the detection
wavelength 238 nm. Linearity was tested at four concen-
trations (0.2, 0.5, 1 and 2 mg/ml): the limit of quantification
was found to be 0.05 mg/ml (9–10).
RESULTS AND DISCUSSION
Nature of the formulations. Since the rate of transdermal
permeation of a topical drug is dependent on the properties
of the compound and also the physico-chemical character-
istics of the vehicle, in which the compound is dissolved or
dispersed, vehicles for topical HCA considered here include
different formulations: two aqueous systems (hydrophilic
emulsion, A and aqueous gel, B); and two systems where
hydrophobicity is dominant (hydrophobic emulsion, C and
ointment, D).
Microemulsions are emulsions producing a transparent
product that has a very small droplet size and does not have
tendency to coalesce. A large amount of drug can in fact be
incorporated in these formulations, due to the high solubiliz-
ing capacity of hydrophobic drugs.
Formulation A is a hydrophilic microemulsion containing
different components (Table I). Labrasol, originally devel-
oped for solubilization of hydrophobic drugs (HLB 14), is a
non-ionic emulsifier, useful also in oral formulations for its
high tolerance and low toxicity in animals; it also displays a
strong absorption enhancing effect (11). Labrasol can be
easily dissolved in water; because it displays only a low
interfacial tension with water, the amount of co-surfactants
can be kept low. Labrafil, is a non-ionic amphiphilic excipient,
used as a co-surfactant in microemulsions. Although Labrafil
is a polyethylene glycol derivative, the presence of fatty acids
(mainly oleic acid) in this non-ionic amphiphilic compound
granted hydrophobic properties to the molecule. This com-
pound, coupled with polyglyceryl di-oleate (Plurol oleique),
builds up the necessary surfactant and co-surfactant system
for the preparation of the microemulsion.
Formulation C represents an example of a self-micro-
emulsifying drug delivery systems and is an isotropic mixture
of oil (vaseline oil), surfactant/co-surfactant and drug: a fine
o/w microemulsion is rapidly formed when the components
are introduced into water.
Generally, gels contain organic macromolecules forming
a tridimensional skeleton with a high solvation degree: the
present gel (Formulation B) is made from the unique water-
soluble component, Sepigel 305, that is a blend of three
ingredients (Polyacrylamide, C13–14 Isoparaffin and Lau-
reth-7) providing increased viscosity, stability and shine to the
formulation. Sepigel 305 is non-ionic and is stable over a wide
range of pH values; after addition, it rapidly disperses under
agitation assuming a pleasant, creamy, gel-like consistency:
the viscosity increase is almost instantaneous.
The ointment (Formulation D) is a viscous semisolid
preparation, hydrophobic in nature, where vaseline, a non-
drying oil, disperses soft petroleum jelly or petrolatum, a
semi-solid mixture of hydrocarbons; systems of this type
spread easily, are protective, hydrating and lubricating.
Solubility of hydrocortisone acetate. Knowledge of the
drug’s solubility for each vehicle composition is necessary to
avoid preparation supersaturation: when the drug concentra-
tion is increased above its equilibrium solubility, the system
becomes thermodynamically unstable and crystallization and
precipitation of excess drug occurs over time. The drug
solubility in the vehicle is also an important factor for drug
penetration across the skin or artificial membranes: the
solubility of the drug in the vehicle will influence both the
drug concentration gradient in the solution and partition
coefficient between the vehicle and the membrane.
HCA has a low solubility in water, but it is more soluble in
propylene glycol,where the saturated solubility is115 mg/100 ml:
Table II. HCA Solubility (±Standard Deviation) in the Four Systems and Release of HCA from the Four Formulations
Formulation Solubility (μg/ml) Released after 8 h (μg) (released/dissolved ratio) Diffusional exponent (n) and constant k(10
2)
A 2,110±20 188±33 (0.09) 0.56/2.3
B 1,774±15 246±11 (0.14) 0.56/1.9
C 2,370±22 265±22 (0.11) 0.50/3.2
D 562±6 163±20 (0.29) 0.51/8.3
Table III. HCA Permeation Parameters from the Four Formulations
Formulation Solubility (S, μg/ml) Flux (J, μg/cm
2h) Permeability coefficient Kp.10
4 (J/S, cm/h)
A 2,110±20 130±10 630±58
B 1,774±15 2±1 11±6
C 2,370±20 133±15 560±60
D 562±6 0.4±0.2 8±4
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parent compound hydrocortisone contains only two hydro-
philic contributions on the steroid rings and in HCA the
hydroxy in the 21 position is masked by the ester linkage with
acetate moiety. A low solubility in water and a high partition
coefficient value is therefore not surprising. LogP value is
1.61 for hydrocortisone and increases up to 2.30 for HCA, as
a consequence of the masking of a hydroxy group (12). The
solubility of HCA in water measured at 37 °C is 10 μg/ml,
m u c hl o w e rt h a nt h a tr e p o r t e di nT a b l eII for the different
systems, suggesting a solubilization ability of all components
used to prepare present formulations: this is particularly
interesting in view of the formation of a concentration
gradient, necessary for the release. HCA solubility is higher
in formulations A and C, due to the presence of co-solvents
or to surfactant compounds able to drive micelle solubiliza-
tion. Solubility in ointment D is the lowest value found. All
the values of the released HCA after 8 h are well below the
starting amount of the dissolved drug in each formulation:
these systems also potentially represent reservoir systems,
since they also contain undissolved drug.
Release from the formulations. Each formulation was
tested for the release of the drug through a dialysis
membrane, which should not offer resistance to the crossing
of the drug: the receptor phase contained ethanol to improve
solubility of the drug and avoid back passage. Table II shows
the results of the release for the different formulations as a
function of time: the test demonstrated that all the formula-
tions have the ability to release HCA to a comparable extent,
despite differences in solubility. The release profiles are
almost parallel for all the formulations (Fig. 1): the amount
released increases with a characteristic profile during a first
period of 8 h; and then reaches the 24 h value very slowly: in
the second period of 16 h the amount released represents
only about 15% of the total (not shown in Figure). The
released amount after 8 h is comparable for the different
formulations, ranging from 163 μg from the ointment (D) to
265 μg for microemulsion systems. The comparison between
solubility in the vehicle and medium ability to release the
drug suggests that the main driving force for HCA release is
the concentration gradient of the dissolved drug. A rapid and
consistent release from a topical formulation first involves the
Fig. 1. HCA release profiles from the four formulations: unfilled triangle hydrophilic microemulsion;
unfilled square aqueous gel; filled diamond lipophilic microemulsion; filled square ointment
Fig. 2. Relationship between HCA amount released after 24 h from the four formulations and solubility
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systems, dissolution must not represent an obstacle to the
supply of the active agent, when this is present in a topical
formulation for transdermal absorption. When the dissolved/
released amount ratio is considered, the highest value is
found for the ointment, suggesting that in this vehicle the
solute displays high mobility. A linear relationship can be
found between the dissolved and released amount after 8 h as
shown in Table II (Fig. 2): the amount released is high when
solubility is high, indicating that the dissolved fraction drives
the release. Formulation A does not adhere to this rule, since
its release value appears lower than that expected. This fact
suggests that HCA in the aqueous microemulsion attains a
particular stability (also due to micelle solubilization, see
below) that delays its release. On the contrary, the behaviour
of non-aqueous microemulsion is more linear, since high
release of the drug corresponds to high solubility.
When experimental data are plotted against time in
terms of the simplified equation:
Mt
M1
¼ kt n
(where: Mt=mass released at time t; M1 starting mass at t=0;
k=diffusional constant that depends on the characteristics of
the formulations; n=diffusional exponent), it could be possi-
ble to obtain further information on the release process. n
values proved similar for all the formulations in the range
0.50–0.56, very close to the reference values for a Fick type
release kinetics, where the release rate decreases with time.
Diffusional constant k values, as obtained by the graphical
solution of the equation, suggest that the release rate is of the
same order of magnitude for the four formulations and that the
release of the drug is affected to a limited extent by technolog-
ical forms employed for the release.
The diffusional constant k suggests that ointment (D)
allows better diffusion of the drug from the bulk toward the
interfaces formulation/dialysis membrane; while aqueous gel
(B) slows down diffusion. In this case it must be taken into
account diffusional difficulties in gelified systems of semisolid
consistency and also the scarce affinity of the hydrophobic
solute towards the aqueous medium.
Effect of the vehicles on HCA permeation. Table III
shows that formulations A and C allow a notable permeation
of the drug after 8 h. Formulations B and D on the contrary
display low permeated amount and low flux, the value related
to the ointment D being the lowest one. Improved flux and
permeation can result from the microemulsion components
(surfactants and co-surfactants) (13,14); moreover also Trans-
cutol is present in both types of microemulsions and it is well
known that it significantly increases the percutaneous pene-
Fig. 3. HCA Permeation profiles from: unfilled triangle hydrophilic microemulsion (A); filled diamond
lipophilic microemulsion (C)
Fig. 4. Permeation profiles of HCA from: unfilled square aqueous gel (B); filled square ointment (D)
766 Fini et al.tration of various active substances, particularly if used in
combination with suitable cosolvents (15,16). This association
is present in formulation C, where propylene glycol acts with
a possible synergistic enhancer effect and this accounts first
for the satisfactory solvent power and second for the skin
penetration enhancing properties of the hydrophobic micro-
emulsion (1) (Fig. 3).
This is not the only mechanism that operates in the
presence of microemulsions. Microemulsions in fact have a
very low interfacial tension that improves the contact
between vehicle and membrane surface; moreover the high
loading capacity of microemulsions ensures a concentration
gradient suitable to improve permeation of the drug (17); also
the occurrence of supersaturation cannot be excluded (18),
which should further increase the gradient.
The high solubility of the drug in systems A and C
provides the necessary concentration gradient for high
permeation: however, though higher with respect to formula-
tions B, and especially D, it does not appear as high as
expected, despite the presence of Transcutol in the formula-
tion. Formulation C in fact contains almost 40% Transcutol,
which, beside its notable transdermal permeation enhance-
ment, also behaves as a solubilizer. It cannot be excluded that
in this aqueous microemulsioned system (C), due to the high
concentration of the surfactant Labrasol, the drug can be
distributed over three different phases: the dispersed phase,
the continuous phase and the surfactant micelles. The
presence of solubilized drug tends to lower the drug
concentration available for permeation, altering the drug
partition process between the system and the membrane.
Formulations B and D can be suggested when it is
desirable to minimize HCA absorption, so as to keep the drug
restricted to the diseased area (Fig. 4): in this case topical
administration offers the advantage of avoiding potential side
effects associated with systemic exposure. Skin permeation
can be inhibited as the affinity with the vehicle becomes
greater than that the affinity with the membrane and this
creates a poor transfer from the vehicle to the skin, as in the
case of the ointment. Difficulty in releasing the drug was
already demonstrated by this formulation also towards the
dialysis membrane, therefore a low permeation promotion
was expected from formulation D: in fact ointment is a
hydrophobic system where the hydrophobic drug can accom-
modate and display little tendency to diffuse outwards. The
lack of any type of enhancer can explain the low drug
permeation in these last cases. In addition, due to the
complete aqueous nature of gel, its application can be found
to be cosmetically more attractive, compared with the
‘‘greasy’’ sensation often experienced after the use of oint-
ments. Gel is less dense and therefore generally easier to
apply to and spread on the skin surface. This may have
important clinical implications, especially if the diseased area
is inflamed and sensitive to mechanical shearing forces.
As a result of the flux obtained, these formulations can
be suggested for maintaining HCA on the skin surface or for
its promotion across the horny layer to the systemic
circulation. In this respect formulations B and D prove useful
for, e.g., topical anti-micotic action on the skin surface or
against psoriasis or dermal affections related to an increased
cell turnover; or to promote anti-inflammatory activity below
the site of application with the reduction of secretion of
chemotactic and vasoactive factors. Formulations A and C
appear optimal vehicles exerting a high capacity for incorpo-
rating HCA and promote its skin permeation and can be
suggested when HCA absorption is required or, in more
general terms, for drugs that need to be absorbed to exert
their therapeutical activity, even though an important disad-
vantage of aqueous microemulsions is that they require a high
content of surfactants, which in turn induce significant
alterations to the skin barrier function and can lead to
possible allergic reactions.
CONCLUSIONS
Experimental results allow the conclusion that gel and
ointment represent suitable formulations to minimize absorp-
tion of topically applied HCA.
Hydrophilic and hydrophobic microemulsions promote
HCA absorption, due to the presence in both formulations of
Transcutol, as solubilizer and permeation enhancer.
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